ATC 2017
Antibody Therapeutics Conference

# Curriculum Vitae

| Name: Eric Tsao |
| --- |
| Affiliation: CEO, Synermore Biologics Co., Ltd. |
| Short Biography (maximum of 400 words): |
| Dr. Eric Tsao has served as the Chief Executive Officer of Synermore Biologics since the founding of the company in 2013. He has over 25 years of direct experience with more than 20 products in clinical development, four US and EU approved products on the market, and eight biotech manufacturing facilities. His areas of expertise include biological product development, process design, facility engineering, and operations. Since 2008, Dr. Tsao has worked with Morningside Venture on biotech investments. He was instrumental in enhancing portfolio companies' CMC capabilities. Dr. Tsao was the Vice President of Technical Operations at Aeras, a Gates Foundation sponsored vaccine development organization, leading the Process Development, Manufacturing, Quality Control, and Facility Engineering functions. At MedImmune, Dr. Tsao rose to the position of Vice President of Process and Manufacturing Sciences responsible at different times for the process development as well as clinical and commercial manufacturing of monoclonal antibodies and recombinant vaccines. The development and manufacturing efforts led to the successful licensing of Synagis, FluMist, and Cervarix. He was a process development scientist at Johnson & Johnson, where he focused on the development of cell culture processes and start-up of the commercial manufacturing facility for erythropoietin. Dr. Tsao received his Ph.D. in Chemical Engineering from the University of Michigan and a B.S. in Chemical Engineering from Tunghai University in Taiwan. |

# Speech Summary at ATC 2017

ATC 2017
Antibody Therapeutics Conference

| Speech Title: | Development of Anti-Rabies MAbs for Post-Exposure Prophylaxis |
|---|---|

Speech Summary (200-400 words)

SYN023 is a mixture of two anti-rabies humanized monoclonal IgG1κ antibodies which bind to distinct and non-overlapping antigenic sites on the rabies virus glycoprotein. The proposed indication for SYN023 is the post-exposure prophylaxis of rabies virus infection, in conjunction with rabies vaccine. SYN023 has shown high binding affinities and broad-spectrum neutralization activities. Protection against virus challenges was demonstrated in various animal models. Phase 1 and Phase 2 human clinical trials were conducted in the U.S. to evaluate the pharmacokinetics, pharmacodynamics, and safety of the product. The strategies for product development and results from the clinical trials will be presented.